ClinicalTrials.gg
RecruitingNCT06701812Updated Nov 4, 2026

Digoxin Medulloblastoma Study

A Phase 2 interventional study of Digoxin in Medulloblastoma and Medulloblastoma, Non-WNT/Non-SHH, sponsored by H. Lee Moffitt Cancer Center and Research Institute. Recruiting at 18 sites in United States. Open to participants aged 12 Months to 30 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by H. Lee Moffitt Cancer Center and Research Institute · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 4, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
12 Months to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 245 studies in Medulloblastoma with a site in United States — 26 open to participants now, 53 under way, 2 of them phase 3. Medulloblastoma · United States.

Planned enrollment
132nd of 215
23 · median 30
Started
2026
with 8 others
Phase 2
65 of 245
5 open now
Primary completion
2027-02
later than 18 of 52 live
Registered
235th of 245
by date

Among the 245 studies in Medulloblastoma with a site in United States, this one is the 132nd largest by planned enrollment of the 215 interventional ones that give a count, is one of 9 that started in 2026, is one of 65 in phase 2, reaches primary completion later than 18 of the 52 other live ones, and was the 235th registered.

Medulloblastoma

317 studies on the registry are indexed under Medulloblastoma; 52 are open to participants now.

Browse Medulloblastoma studies →

Open to participants now

26 of the 245 studies in Medulloblastoma with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Medulloblastoma studies recruiting now, 4 (11%) set no upper age limit and 32 (84%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.

This study: 12 Months to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Medulloblastoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.

03

Conditions studied

  • Medulloblastoma
  • Medulloblastoma, Non-WNT/Non-SHH

Browse trials for

04

Who can participate

Ages eligible
12 Months to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be age >12 months and \<30 years at the time of enrollment.
  • Patients must have non-WNT, non-SHH medulloblastoma confirmed by a CAP/CLIA certified assay (such as nanostring or methylation) performed on tissue from diagnosis or relapse.
  • Patients must have received at least one prior course of chemotherapy for their medulloblastoma. They must also have received irradiation.
  • Prior therapy: Therapy may not have been received more recently than the timeframes defined below: Craniospinal radiotherapy: At least 3 months have elapsed since prior craniospinal radiotherapy (at doses ≥ 18 Gy). Local radiotherapy: At least 3 months since prior local radiotherapy to primary tumor. Focal radiotherapy: At least 2 weeks since prior focal radiotherapy to symptomatic sites. Myelosuppressive chemotherapy and/or immunotherapy and/or biologics: More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas), immunotherapy, or biologics. Hematopoietic growth factor: Seven days must have elapsed since the completion of therapy with colony-stimulating factors (e.g., filgrastim [G-CSF], sargramostim [GM-CSF], or erythropoietin), or -stimulating agents.
  • Patients must have recovered from any surgical procedures such as , with neurological stability for > 7 days.
  • Patients must have clear residual disease, defined as tumor that is measurable in two perpendicular diameters on MRI (ie, largest tumor diameter and its largest perpendicular). The size of a at baseline should be at least 2 times the thickness of the slices showing the tumor (adding the interslice gap).
  • Patients must have a Lansky or performance status score of ≥ 50%. Use Karnofsky for patients > 16 years of age and Lansky for patients \< 16 years of age. Patients who are unable to ambulate but who are functional in a wheelchair will be considered ambulatory for the purpose of assessing the performance score.
  • Patients must have normal organ and marrow function.
  • Patient has no evidence of Wolff-Parkinson-White syndrome or high-grade AV block (form of second-degree heart block) on screening .
  • Patient has no evidence of hypertrophic obstructive cardiomyopathy on screening echo.
  • Any patient that reports recent palpitations (within the last month), or concerning findings on echo or ECG must be evaluated and cleared for treatment with digoxin by a cardiologist prior to enrollment. Study PI should be contacted for additional questions/concerns regarding these patients.
  • Patients receiving concurrent dexamethasone are eligible, provided dosage is stable or decreasing for ≥7 days prior to study enrollment.
  • Patients must have a stable neurologic status for ≥7 days prior to study enrollment. If a patient experiences neurologic decline following enrollment but prior to day 1 of cycle 1, they should be reassessed for eligibility.
  • Pregnancy: Females of must have a negative urine or serum pregnancy test prior to enrollment. Female patients who are lactating must agree to stop breastfeeding.
  • Women of child-bearing potential and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  • All patients and/or their parents or legal guardians must have the ability to understand and the willingness to sign a written or assent document.

Exclusion criteria

Exclusion Criteria:

  • Participants who are receiving concurrent anticancer or any other agents are ineligible.
  • Participants taking digoxin for any reason during treatment for initial diagnosis of medulloblastoma or relapse are ineligible. Exposure to digoxin therapy prior to initial diagnosis of medulloblastoma is allowed.
  • Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to digoxin are ineligible.
  • Patients with serious or inadequately controlled cardiac arrhythmias, including baseline ectopy, ventricular tachycardia, frequent premature ventricular contractions (PVCs), or symptomatic sinus bradycardia are excluded from the study.
  • Patients taking medications that are known to interfere with digoxin metabolism are ineligible.
  • Participants with uncontrolled intercurrent illness, concurrent unrelated systemic illness (e.g. serious infection) or significant cardiac, pulmonary, hepatic, or other organ dysfunction that would compromise the patient's ability to tolerate study treatment or would likely interfere with study procedures or results are ineligible.
  • Participants with psychiatric illness/social situations that would limit compliance with study requirements are ineligible.
  • Pregnant women or women unwilling to stop breastfeeding are excluded from this study because it is unknown how pregnant women with recurrent medulloblastoma will metabolize and tolerate digoxin. There is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with digoxin in this setting.
  • Participants who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (estimated)

Study arms

  • Experimental
    Digoxin Treatment

    Digoxin will be administered orally at a standard maintenance dosing. Each cycle will be 28 days.

    Drug: Digoxin

Interventions

  • 2.5-10 mcg/kg/day orally divided twice daily or once daily based on age on a continuous dosing schedule.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival at 4 months (PFS4)

    Proportion of patients with progression free survival at 4 months after initiation of treatment.

    Time frame: 4 months

Secondary outcomes

  1. Response rate

    Response rate is defined as complete response (CR) + partial response (PR) at 4 months after initiation of study treatment.

    Time frame: 4 months

  2. Stable Disease (SD)

    Stable disease rate as defined as stable disease (SD) at 4 months after initiation of study treatment.

    Time frame: 4 months

  3. Event Free Survival

    Event Free Survival as defined as time from first dose of protocol therapy to secondary malignancy, death, or progression, whichever comes first.

    Time frame: Up to 12 months

07

Study locations

17 of 18 sites recruiting
  • University of Alabama at Birmingham Children's of Alabama
    Birmingham, Alabama 35233, United States
    Recruiting
    • Laura Metrock, MD · Principal investigator
  • Phoenix Childrens Hospital
    Phoenix, Arizona 85016, United States
    Recruiting
    • Ross Mangum, MD · Principal investigator
  • Arkansas Childrens Hospital
    Little Rock, Arkansas 72202, United States
    Recruiting
    • David Douglass, MD · Principal investigator
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
    Recruiting
    • Michael Isakoff, MD · Principal investigator
  • Children's National Medical Center
    Washington D.C., District of Columbia 20010, United States
    Recruiting
    • Eugene Hwang, MD · Principal investigator
  • Nemours Jacksonville
    Jacksonville, Florida 32207, United States
    Not yet recruiting
    • Darren Klawinski, MD · Principal investigator
  • University of Miami
    Miami, Florida 33136, United States
    Recruiting
    • Bradley Gampel, MD · Principal investigator
  • Nemours Children's Hospital Orlando
    Orlando, Florida 32827, United States
    Recruiting
    • Vibhuti Agarwal, MD · Principal investigator
  • Johns Hopkins All Children's
    St. Petersburg, Florida 33701, United States
    Recruiting
    • Stacie Stapleton, MD · Principal investigator
  • St. Joseph's Children's Hospital
    Tampa, Florida 33607, United States
    Recruiting
    • Trisha Larkin, MD · Principal investigator
  • University of Kentucky
    Lexington, Kentucky 40536, United States
    Recruiting
    • Tom Badgett, MD, PhD · Principal investigator
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21218, United States
    Recruiting
    • Kenneth Cohen, MD · Principal investigator
  • Washington University St. Louis
    St Louis, Missouri 63130, United States
    Recruiting
    • Mohamed Abdelbaki, MD · Principal investigator
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
    Recruiting
    • Alice Lee, MD · Principal investigator
  • UNC Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina 27514, United States
    Recruiting
    • David Kram, MD · Principal investigator
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
    Recruiting
    • Erin Trovillion, MD · Principal investigator
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Recruiting
    • Scott Borinstein, MD · Principal investigator
  • UT Southwestern
    Dallas, Texas 75390, United States
    Recruiting
    • Matthew Campbell, MD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Feb 2027, 13 months after the start.

Of 38 non-industry phase 2 interventional studies under Medulloblastoma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 114. This study's planned 13 months is below that.

Counting every sponsor, half of 42 studies reached it within 66 months; a quarter within 51 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Nov 22, 2024
StartActual
Jan 15, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Nemours Children's Hospital Orlando · Orlando, United States
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    1 site added
    Show site
    • Nemours Children's Hospital Orlando · Orlando, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06701812
Collaborators
National Pediatric Cancer Foundation
Responsible party
Sponsor
First posted
Nov 22, 2024
Start date
Jan 15, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Jessica Crimella
Contact
Jessica.Crimella@moffitt.org
813-745-6250
Laura Metrock, MD
principal investigator · University of Alabama at Birmingham Children's of Alabama
Jonathan Metts, MD
study chair · Moffitt Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Digoxin

Start the discussion